Search

Your search keyword '"Naka H"' showing total 47 results
Start Over "Naka H" Publisher lippincott williams & wilkins
47 results on '"Naka H"'

1. Efficacy of semi-customized exercises in preventing low back pain in high school volleyball players: A randomized controlled trial.

Author

Mizoguchi Y, Akasaka K, Otsudo T, Shimada N, and Naka H

Subjects
Humans, Range of Motion, Articular, Schools, Low Back Pain epidemiology, Low Back Pain prevention & control, Muscle Stretching Exercises, Volleyball
Abstract

Background: Low back pain (LBP) is a common injury in high school volleyball players. We hypothesized that a prevention program could decrease the incidence of LBP in high school volleyball players. This study was an in-season cluster-randomized controlled trial., Methods: We block-randomized 8 high school volleyball teams comprising 70 players aged 15 to 17 years into the intervention (4 teams, 34 players) and control (4 teams, 36 players) groups. The intervention program consisted of 9 physical function tests as well as 1 or 2 self-selected preventive exercises, including dynamic thoracic mobility, trunk stabilization exercises, and static stretching, performed during warm-up. Both groups were followed up for 4 weeks, during which the incidence of LBP was recorded. Physical function tests (back endurance; spinal and back flexibility; active or passive shoulder and trunk range of motion; ankle joint mobility; and iliopsoas, quadriceps, and hamstrings flexibility) were conducted before and after the intervention., Results: The intervention group had a significantly lower incidence of LBP (8.8%) than the control group (33.3%) (relative risk, 3.78; 95% confidence interval, 1.17-12.23; P = .017, 1 - β = 0.99). Lumbar extension accounted for nearly 70% of LBP incidences. Most players in the intervention group demonstrated improved physical function associated with the exercises., Conclusion: The semi-customized prevention program decreased the incidence of LBP and enhanced the physical function parameter in high school volleyball players., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2022
Full Text
View/download PDF

2. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis.

Author

Charidimou, Andreas, Imaizumi, Toshio, Moulin, Solene, Biffi, Alexandro, Samarasekera, Neshika, Yakushiji, Yusuke, Peeters, Andre, Vandermeeren, Yves, Laloux, Patrice, Baron, Jean-Claude, Hernandez-Guillamon, Mar, Montaner, Joan, Casolla, Barbara, Gregoire, Simone M., Kang, Dong-Wha, Kim, Jong S., Naka, H., Smith, Eric E., Viswanathan, Anand, and Jäger, Hans R.

Published
2017
Full Text
View/download PDF

3. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA A meta-analysis

Author

Wilson, D, Charidimou, A, Ambler, G, Fox, ZV, Gregoire, S, Rayson, P, Imaizumi, T, Fluri, F, Naka, H, Horstmann, S, Veltkamp, R, Rothwell, PM, Kwa, VIH, Thijs, V, Lee, Y-S, Kim, YD, Huang, Y, Wong, KS, Jager, HR, Werring, DJ, Wilson, D, Charidimou, A, Ambler, G, Fox, ZV, Gregoire, S, Rayson, P, Imaizumi, T, Fluri, F, Naka, H, Horstmann, S, Veltkamp, R, Rothwell, PM, Kwa, VIH, Thijs, V, Lee, Y-S, Kim, YD, Huang, Y, Wong, KS, Jager, HR, and Werring, DJ

Abstract

OBJECTIVE: To determine associations between cerebral microbleed (CMB) burden with recurrent ischemic stroke (IS) and intracerebral hemorrhage (ICH) risk after IS or TIA. METHODS: We identified prospective studies of patients with IS or TIA that investigated CMBs and stroke (ICH and IS) risk during ≥3 months follow-up. Authors provided aggregate summary-level data on stroke outcomes, with CMBs categorized according to burden (single, 2-4, and ≥5 CMBs) and distribution. We calculated absolute event rates and pooled risk ratios (RR) using random-effects meta-analysis. RESULTS: We included 5,068 patients from 15 studies. There were 115/1,284 (9.6%) recurrent IS events in patients with CMBs vs 212/3,781 (5.6%) in patients without CMBs (pooled RR 1.8 for CMBs vs no CMBs; 95% confidence interval [CI] 1.4-2.5). There were 49/1,142 (4.3%) ICH events in those with CMBs vs 17/2,912 (0.58%) in those without CMBs (pooled RR 6.3 for CMBs vs no CMBs; 95% CI 3.5-11.4). Increasing CMB burden increased the risk of IS (pooled RR [95% CI] 1.8 [1.0-3.1], 2.4 [1.3-4.4], and 2.7 [1.5-4.9] for 1 CMB, 2-4 CMBs, and ≥5 CMBs, respectively) and ICH (pooled RR [95% CI] 4.6 [1.9-10.7], 5.6 [2.4-13.3], and 14.1 [6.9-29.0] for 1 CMB, 2-4 CMBs, and ≥5 CMBs, respectively). CONCLUSIONS: CMBs are associated with increased stroke risk after IS or TIA. With increasing CMB burden (compared to no CMBs), the risk of ICH increases more steeply than that of IS. However, IS absolute event rates remain higher than ICH absolute event rates in all CMB burden categories.

Published
2016

4. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: A meta-analysis.

Author

Wilson D, Charidimou A, Ambler G, Fox ZV, Gregoire S, Rayson P, Imaizumi T, Fluri F, Naka H, Horstmann S, Veltkamp R, Rothwell PM, Kwa VI, Thijs V, Lee YS, Kim YD, Huang Y, Wong KS, Jäger HR, and Werring DJ

Subjects
Brain Ischemia diagnostic imaging, Cerebral Hemorrhage diagnostic imaging, Humans, Recurrence, Risk, Stroke diagnostic imaging, Brain Ischemia epidemiology, Cerebral Hemorrhage epidemiology, Stroke epidemiology
Abstract

Objective: To determine associations between cerebral microbleed (CMB) burden with recurrent ischemic stroke (IS) and intracerebral hemorrhage (ICH) risk after IS or TIA., Methods: We identified prospective studies of patients with IS or TIA that investigated CMBs and stroke (ICH and IS) risk during ≥3 months follow-up. Authors provided aggregate summary-level data on stroke outcomes, with CMBs categorized according to burden (single, 2-4, and ≥5 CMBs) and distribution. We calculated absolute event rates and pooled risk ratios (RR) using random-effects meta-analysis., Results: We included 5,068 patients from 15 studies. There were 115/1,284 (9.6%) recurrent IS events in patients with CMBs vs 212/3,781 (5.6%) in patients without CMBs (pooled RR 1.8 for CMBs vs no CMBs; 95% confidence interval [CI] 1.4-2.5). There were 49/1,142 (4.3%) ICH events in those with CMBs vs 17/2,912 (0.58%) in those without CMBs (pooled RR 6.3 for CMBs vs no CMBs; 95% CI 3.5-11.4). Increasing CMB burden increased the risk of IS (pooled RR [95% CI] 1.8 [1.0-3.1], 2.4 [1.3-4.4], and 2.7 [1.5-4.9] for 1 CMB, 2-4 CMBs, and ≥5 CMBs, respectively) and ICH (pooled RR [95% CI] 4.6 [1.9-10.7], 5.6 [2.4-13.3], and 14.1 [6.9-29.0] for 1 CMB, 2-4 CMBs, and ≥5 CMBs, respectively)., Conclusions: CMBs are associated with increased stroke risk after IS or TIA. With increasing CMB burden (compared to no CMBs), the risk of ICH increases more steeply than that of IS. However, IS absolute event rates remain higher than ICH absolute event rates in all CMB burden categories., (© 2016 American Academy of Neurology.)

Published
2016
Full Text
View/download PDF

5. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies.

Author

Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Sorimachi T, Werring DJ, Gregoire SM, Imaizumi T, Lee SH, Briley D, Rothwell PM, Edinburgh Stroke Study Group, Lovelock, Caroline E, Cordonnier, Charlotte, Naka, Hiromitsu, Al-Shahi Salman, Rustam, Sudlow, Cathie L M, Sorimachi, Takatoshi, and Werring, David J

Published
2010
Full Text
View/download PDF

8. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.

Author

Greenberg, Steven M., Ziai, Wendy C., Cordonnier, Charlotte, Dowlatshahi, Dar, Francis, Brandon, Goldstein, Joshua N., Hemphill III, J. Claude, Johnson, Ronda, Keigher, Kiffon M., Mack, William J., Mocco, J., Newton, Eileena J., Ruff, Ilana M., Sansing, Lauren H., Schulman, Sam, Selim, Magdy H., Sheth, Kevin N., Sprigg, Nikola, Sunnerhagen, Katharina S., and Hemphill, J Claude 3rd

Published
2022
Full Text
View/download PDF

9. Cerebral Microbleeds: Relationship to Antithrombotic Medications.

Author

Graff-Radford, Jonathan, Lesnick, Timothy, Rabinstein, Alejandro A., Gunter, Jeffrey L., Przybelski, Scott A., Noseworthy, Peter A., Preboske, Gregory M., Mielke, Michelle M., Lowe, Val J., Knopman, David S., Petersen, Ronald C., Kremers, Walter K., Jack Jr., Clifford R., Vemuri, Prashanthi, Kantarci, Kejal, and Jack, Clifford R Jr

Published
2021
Full Text
View/download PDF

15. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.

Author

Ryan, Joanne, Storey, Elsdon, Murray, Anne M., Woods, Robyn L., Wolfe, Rory, Reid, Christopher M., Nelson, Mark R., Chong, Trevor T. J., Williamson, Jeff D., Ward, Stephanie A., Lockery, Jessica E., Orchard, Suzanne G., Trevaks, Ruth, Kirpach, Brenda, Newman, Anne B., Ernst, Michael E., McNeil, John J., Shah, Raj C., and ASPREE Investigator Group

Published
2020
Full Text
View/download PDF

17. MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation.

Author

Martí-Fàbregas, Joan, Medrano-Martorell, Santiago, Merino, Elisa, Prats-Sánchez, Luis, Marín, Rebeca, Delgado-Mederos, Raquel, Martínez-Domeño, Alejandro, Camps-Renom, Pol, Jiménez-Xarrié, Elena, Zedde, Mariluisa, Gómez-Choco, Manuel, Lara, Lidia, Boix, Amèlia, Calleja, Ana, De Arce-Borda, Ana María, Bravo, Yolanda, Fuentes, Blanca, Hernández-Pérez, María, Cánovas, David, and Llull, Laura

Published
2019
Full Text
View/download PDF

24. New cerebral microbleeds in AF patients on non-vitamin K oral anticoagulants or warfarin: One-year follow-up.

Author

Zhuang L, Zhai L, Qiao S, Hu X, Lai Q, Fu F, Cheng L, Liu L, Liu X, and Wang J

Subjects
Administration, Oral, Anticoagulants adverse effects, Cerebral Hemorrhage chemically induced, Cerebral Hemorrhage diagnostic imaging, Cerebral Hemorrhage epidemiology, Follow-Up Studies, Humans, Vitamin K therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Warfarin adverse effects
Abstract

Abstract: Anticoagulant treatment increases the risk of intracerebral hemorrhage (ICH), but whether the treatment, more specifically non-vitamin K oral anticoagulants (NOACs), increases the risk of cerebral microbleeds (CMBs) remains uncertain. We performed this study to investigate the development of new CMBs due to NOACs or warfarin treatment in patients with atrial fibrillation (AF).We prospectively recruited AF patients before anticoagulation from June 2016 to June 2018. We performed susceptibility-weighted imaging (SWI) examinations on all enrolled AF patients and re-examined SWI 1 year later. We compared demographic features and new CMBs between the NOACs group and the warfarin group. Univariate analysis of clinical factors was performed according to the development of new CMBs; and age, a HAS-B(L)ED score, warfarin use, and the presence of baseline CMBs were then selected for inclusion in the multivariate logistic regression model.A total of 72 AF patients were recruited, 29 of whom were assigned to the NOACs group and 43 to the warfarin group. Finally, 1 patient in the NOACs group (3.4%) and 9 patients (20.9%) in the warfarin group developed new CMBs after 1 year follow-up (P = .08). Univariate analysis showed that age, a HAS-B(L)ED score ≥4, the presence of baseline CMBs were associated with the development of new CMBs (P < .05). And multivariate regression analysis showed baseline CMBs (P = .03, odds ratio = 6.37, 95% confidence interval 1.15-35.36) was independently related to the increase in new CMBs.AF patients treated with NOACs may have a decreased trend in the development of new CMBs compared with those treated with warfarin. Baseline CMBs increased the frequency of new CMBs during anticoagulant treatment. The development of new CMBs in AF patients with anticoagulation requires further longitudinal studies with longer follow-up in larger samples., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2022
Full Text
View/download PDF

31. Anticoagulant management by low-dose of low molecular weight heparin in patients with nonvalvular atrial fibrillation following hemorrhagic transformation and complicated with venous thrombosis: Five case reports and literature review.

Author

Zhang L, Kong YH, Wang DW, Li KT, and Yu HP

Subjects
Aged, Aged, 80 and over, Anticoagulants adverse effects, Female, Heparin, Low-Molecular-Weight adverse effects, Humans, Male, Middle Aged, Retrospective Studies, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Heparin, Low-Molecular-Weight administration & dosage, Stroke prevention & control, Venous Thrombosis drug therapy
Abstract

Abstract: For patients with nonvalvular atrial fibrillation (NVAF) following hemorrhagic infarction (HI)/hemorrhage transformation (HT) and complicated with venous thrombosis, the management of anticoagulation is controversial. Our study intends to explore the safety and effectiveness of using low-dose of low molecular weight heparin (LMWH) to treat NVAF patients with HI (or HT) and complicated with venous thrombosis.Between January 2018 and January 2019, NVAF related acute ischemic stroke patients with HT/HI, hospitalized in the department of neurology or rehabilitation in our hospital, are enrolled retrospectively. Among them, those who were found to have venous thrombosis and undergo anticoagulation (LMWH) during the treatment were extracted. We investigate the efficacy and safety in those patients who have been treated with anticoagulant of LMWH.Five cases accepted LMWH within 3 weeks attributed to the appearance of venous thrombosis, and all of them did not display new symptomatic bleeding or recurrent stroke. However, based on the results of a head computed tomography scan, there were 2 cases of slightly increased intracranial hemorrhage, and then we reduced the dose of anticoagulant. In addition, color ultrasound showed that venous thrombosis disappeared or became stable.Patients with NVAF following HI/HT have a higher risk of thromboembolism. Early acceptance of low-dose LMWH as an anticoagulant is relatively safe and may gain benefit. However, in the process of anticoagulant therapy, we should follow-up head computed tomography/magnetic resonance imaging frequently, as well as D-dimer values, limb vascular ultrasound. Besides, the changes of symptoms and signs should be focused to judge the symptomatic bleeding or recurrent stroke. Furthermore, it is better to adjust anticoagulant drug dosage according to specific conditions., Competing Interests: The authors report no conflicts of interest., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results